Genflow Biosciences PLC Announces Patent Update

Genflow Biosciences PLC Announces Patent Update

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS

Why Genflow Biosciences (LSE:GENF) Is Drawing Fresh Attention in Longevity Research

Discover how Genflow Biosciences (LSE:GENF) is strengthening its longevity research through accelerated US patent examination and expanding global intellectual property protection.

Genflow Biosciences Advances SIRT6 Patent Portfolio In US And Europe

Genflow Biosciences plc (LON:GENF) has announced progress across its two principal SIRT6 patent families covering its centenarian-derived SIRT6 variant (SIRT6c; N308K/A313S). ·      US patent application covering the use of SIRT6c in NAFLD and NASH published ·      Track One prioritised examination granted for the foundational in-licensed US SIRT6 compound of matter patent application ·      Corresponding European application at an advanced stag…

Has Patent Term Adjustment Peaked?

by Dennis Crouch Back in April I wrote that patent term adjustment was still climbing and that the slope showed no sign of leveling. It has now leveled. The six-week trailing average of PTA for newly issued utility patents peaked at 319 days in late May 2026, and has held between 305 and 320 days every week since. See Dennis Crouch, Still Climbing: PTA Hits 318 Days, Back to 2015 Levels, Patently-O (Apr. 21, 2026). To continue reading, become a…